Cannabis Sativa: an integrative review of legal, toxicological and pharmacotherapeutic aspects
DOI:
https://doi.org/10.33448/rsd-v10i15.22408Keywords:
Phytocannabinoids; Cannabis sativa; Central nervous system; Pathologies.Abstract
Currently, with the growing number of studies involving phytocompounds with numerous pharmacological applications, cannabis has taken a leading role in the treatment of numerous pathologies. In this context, delta 9-tetrahydrocannabinol (Δ9 -THC), cannabidiol (CBD), and cannabinol (CBN), present mainly in the Cannabis genus, have gained greater scientific focus as a natural source of these compounds, which, compared to other pharmacological substances, have fewer adverse effects. The search for evidence was conducted in the Medline, PubMed, Scielo, and LILACS databases. Forty-one articles that met the inclusion and quality criteria were selected. It was observed that the scientific literature presents strong evidence for the use of these substances in the treatment of nausea and vomiting associated with chemotherapy, analgesia in chronic pain, anorexia associated with Acquired Immune Deficiency Syndrome (AIDS), neuropathic pain and some neurological diseases such as multiple sclerosis, anxiety, insomnia, epilepsy, and in Parkinson's disease. It is concluded that the use of phytocannabinoids presented a safe toxicological profile for use in both children and adults, not being related to the development of considerable secondary problems or dependence, and their applicability in pharmaceutical formulations in the industrial area is increasing.
References
Appendino, G., Chianese, G., & Taglialatela-Scafati, O. (2011). Cannabinoids: Occurrence and Medicinal Chemistry. Current Medicinal Chemistry, 18(7), 1085–1099.
Araújo, T. Almanaque das Drogas. São Paulo: Leya, 2014.
Baptista, Lucas. (2014). Uso de maconha para o retardo dos efeitos do Alzheimer.
Baker, T. A., Bufalino, M. E., Ford, M. L., & Kale, S. R. (2010). Five Years of Experience with the ConnectOregon Multimodal Funding Program. Transportation Research Record: Journal of the Transportation Research Board, 2174(1), 68–76. https://doi.org/10.3141/2174-10
Blake, A., Wan, B. A., Malek, L., DeAngelis, C., Diaz, P., Lao, N., Chow, E., & O’Hearn, S. (2017). A selective review of medical cannabis in cancer pain management. Annals of Palliative Medicine, 6(S2), S215—S222. https://doi.org/10.21037/apm.2017.08.05
Blessing, E. M., Steenkamp, M. M., Manzanares, J., & Marmar, C. R. (2015). Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics, 12(4), 825–836. https://doi.org/10.1007/s13311-015-0387-1
Bitencourt, R. M., Pamplona, F. A., & Takahashi, R. N. (2008). Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. European Neuropsychopharmacology, 18(12), 849–859. https://doi.org/10.1016/j.euroneuro.2008.07.001
Brucki, S. M. D., Frota, N. A., Schestatsky, P., Souza, A. H., Carvalho, V. N., Manreza, M. L. G., Mendes, M. F., Comini-Frota, E., Vasconcelos, C., Tumas, V., Ferraz, H. B., Barbosa, E., & Jurno, M. E. (2015). Cannabinoids in neurology – Brazilian Academy of Neurology. Arquivos de Neuro-Psiquiatria, 73(4), 371–374. https://doi.org/10.1590/0004-282x20150041
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012). Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philosophical Transactions of the Royal Society B: Biological Sciences, 367(1607), 3364–3378. https://doi.org/10.1098/rstb.2011.0389
Castillo, P. E., Younts, T. J., Chávez, A. E., & Hashimotodani, Y. (2012). Endocannabinoid Signaling and Synaptic Function. Neuron, 76(1), 70–81. https://doi.org/10.1016/j.neuron.2012.09.020
Cannabis medicinal: realidade à espera de regulamentação. (n.d.). Senado Federal. https://www12.senado.leg.br/noticias/infomaterias/2021/07/cannabis-medicinal-realidade-a-espera-de-regulamentacao
Comissão aprova proposta para legalizar no Brasil o cultivo de Cannabis sativa para fins medicinais Fonte: Agência Câmara de Notícias. (n.d.). camara dos deputados. https://www.camara.leg.br/noticias/769630-comissao-aprova-proposta-para-legalizar-no-brasil-o-cultivo-de-cannabis-sativa-para-fins-medicinais
Crippa, J. A. S., Zuardi, A. W., & Hallak, J. E. C. (2010). Uso terapêutico dos canabinoides em psiquiatria. Revista Brasileira de Psiquiatria, 32(suppl 1), 556–566. https://doi.org/10.1590/s1516-44462010000500009
Vries, M., Van Rijckevorsel, D. C. M., Vissers, K. C. P., Wilder-Smith, O. H. G., & Van Goor, H. (2016). Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis patients: analgesic efficacy, pharmacokinetics and tolerability. British Journal of Clinical Pharmacology, 81(3), 525–537. https://doi.org/10.1111/bcp.12811
Di -Marzo, V., Bisogno, T., & De Petrocellis, L. (2001). Anandamide: some like it hot. Trends in Pharmacological Sciences, 22(7), 346–349. https://doi.org/10.1016/s0165-6147(00)01712-0
Ebling- Flores, L., & Zamin, L. L. (2017). Potencial neuroprotetor, antioxidante e anti-inflamatório do Canabidiol: relevância e perspectivas para o tratamento de doenças neurodegenerativas. Revista de Ciências Médicas e Biológicas, 16(2), 224. https://doi.org/10.9771/cmbio.v16i2.20568
Ferreira, S. (2017). Liberação da maconha. Revista Bioética, 25(3), 431–436. https://doi.org/10.1590/1983-80422017253000
Grosso, Adriana F. (2020). Cannabis: de planta condenada pelo preconceito a uma das grandes opções terapêuticas do século. Journal of Human Growth and Development, 30(1), 94-97. https://dx.doi.org/10.7322/jhgd.v30.9977
Grotenhermen, F., & Müller-Vahl, K. (2012). The Therapeutic Potential of Cannabis and Cannabinoids. Deutsches Aerzteblatt Online. https://doi.org/10.3238/arztebl.2012.0495
Hill, K. P., Palastro, M. D., Johnson, B., & Ditre, J. W. (2017). Cannabis and Pain: A Clinical Review. Cannabis and Cannabinoid Research, 2(1), 96–104. https://doi.org/10.1089/can.2017.0017
Honório, K. M., Arroio, A., & Silva, A. B. F. d. (2006). Aspectos terapêuticos de compostos da planta Cannabis sativa. Química Nova, 29(2), 318–325. https://doi.org/10.1590/s0100-40422006000200024
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019). Cannabidiol Adverse Effects and Toxicity. Current Neuropharmacology, 17(10), 974–989. https://doi.org/10.2174/1570159x17666190603171901
International Association for Cannabis as Medicine. (n.d.). cannabis medicine. https://cannabis-med.org/index.php?tpl=def&id=241&lng=en&red=deflist
Lenard II (2012). Levantamento Nacional de Álcool e Drogas. São Paulo (BR): Instituto Nacional de Ciência e Tecnologia para Políticas Públicas do Álcool e Outras Drogas, Universidade Federal de São Paulo [PDF file]. Disponível em: https://inpad.org.br/wp-content/uploads/2014/03/Lenad-II-Relat%C3%B3rio.pdf
Matos L. A. et al, R. (2017). O Uso do Canabidiol no Tratamento da Epilepsia. revista virtual de quimica, 9(2), 786–814.
Mechoulam, R. (2005). Plant cannabinoids: a neglected pharmacological treasure trove. British Journal of Pharmacology, 146(7), 913–915. https://doi.org/10.1038/sj.bjp.0706415
Mercolini, L., Musenga, A., Comin, I., Baccini, C., Conti, M., & Raggi, M. A. (2008). Determination of plasma and urine levels of Δ9-tetrahydrocannabinol and its main metabolite by liquid chromatography after solid-phase extraction. Journal of Pharmaceutical and Biomedical Analysis, 47(1), 156–163. https://doi.org/10.1016/j.jpba.2007.12.023
Mevatyl® - CRF-SP - Conselho Regional de Farmácia do Estado de São Paulo. (2017, 16 de janeiro). Home - CRF-SP - Conselho Regional de Farmácia do Estado de São Paulo. http://www.crfsp.org.br/noticias/8277-mevatyl.html
Morgan, C. J., Freeman, T. P., Schafer, G. L., & Curran, H. V. (2010b). Cannabidiol Attenuates the Appetitive Effects of Δ9-Tetrahydrocannabinol in Humans Smoking Their Chosen Cannabis. Neuropsychopharmacology, 35(9), 1879–1885. https://doi.org/10.1038/npp.2010.58
Müller-Vahl, K., & Grotenhermen, F. (2013). Cannabis Therapy. Deutsches Aerzteblatt Online. https://doi.org/10.3238/arztebl.2013.0144a
Pamplona, F. A. Malcher-Lopes, R. (2014). O ano da mudança. Revista da Biologia, São Paulo, 13(1).
Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9 -tetrahydrocannabinol, cannabidiol and Δ9 -tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215. https://doi.org/10.1038/sj.bjp.0707442
Productos - Bedrocan produce cinco cepas de cannabis medicinal. (n.d.). Bedrocan - beyond pioneering. https://bedrocan.com/es/productos/
Resolução de diretoria colegiada - rdc nº 473, de 24 de fevereiro de 2021 - resolução de diretoria colegiada - rdc nº 473, de 24 de fevereiro de 2021 - dou - Imprensa Nacional. (2021, 3 de março). Home — Português (Brasil). http://antigo.anvisa.gov.br/documents/10181/6236630/%282%29RDC_473_2021_.pdf/7a65445f-52a1-4533-97c7-6d96eff3b8e1
Russo, E. B., Burnett, A., Hall, B., & Parker, K. K. (2005). Agonistic Properties of Cannabidiol at 5-HT1a Receptors. Neurochemical Research, 30(8), 1037–1043. https://doi.org/10.1007/s11064-005-6978-1
Sativex - Bula de Sativex. (n.d.). Bulário. https://www.bulario.com/sativex/
Santos, C. M. C., Pimenta, C. A. M. & Nobre, M. R. C. (2007). A estratégia PICO para a construção da pergunta de pesquisa e busca de evidências. Revista Latino-Americana de Enfermagem, 15(3), 508–511. https://doi.org/10.1590/S0104-11692007000300023.
Solowij, N., Broyd, S. J., Beale, C., Prick, J.-A., Greenwood, L.-m., van Hell, H., Suo, C., Galettis, P., Pai, N., Fu, S., Croft, R. J., Martin, J. H., & Yücel, M. (2018). Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. Cannabis and Cannabinoid Research, 3(1), 21–34. https://doi.org/10.1089/can.2017.0043
Souza, Y. P. (2017). Sínteses e aplicações recentes do ∆ 9 -tetraidrocanabinol (thc) e seus derivados em química medicinal.
Ter item de cultivo de maconha para uso pessoal não justifica ação. (2021a, 22 de setembro). Agência Brasil. https://agenciabrasil.ebc.com.br/justica/noticia/2021-09/justica/noticia/2021-09/ter-item-de-cultivo-de-maconha-para-uso-pessoal-nao-justifica-acao
Korem, N., Zer-Aviv, T. M., Ganon-Elazar, E., Abush, H., & Akirav, I. (2016). Targeting the endocannabinoid system to treat anxiety-related disorders. Journal of Basic and Clinical Physiology and Pharmacology, 27(3). https://doi.org/10.1515/jbcpp-2015-0058
Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in Humans—The Quest for Therapeutic Targets. Pharmaceuticals, 5(5), 529–552. https://doi.org/10.3390/ph5050529
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Daniele Oliveira Cabral Pessoa; Iago Vilar Lira; Lidiany da Paixão Siqueira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
